# Prostate Cancer ### Overview Prostate cancer is one of the best-supported cancer types in the curcumin clinical literature — unusually, there are multiple completed randomised controlled trials in human patients, not just preclinical data. The evidence spans chemoprevention, PSA progression suppression, androgen receptor modulation, PI3K/PTEN pathway targeting, and docetaxel combination. Critically, the human trial results are mixed, and both the positive and negative findings are presented here honestly. *** ### Human Clinical Trial Data **RCT 1 — PSA Progression Suppression: Choi et al. (2019)** This is the most statistically significant positive human trial for curcumin in prostate cancer. It was a randomised, double-blind, placebo-controlled trial in 97 patients with prostate cancer on intermittent androgen deprivation therapy (ADT) — a population where PSA progression during the off-treatment period is a meaningful clinical concern. Key results: * The proportion of patients experiencing PSA progression during the 6-month curcumin period was **10.3% in the curcumin group vs 30.2% in the placebo group (p = 0.0259)** — a statistically significant, clinically meaningful result * In the curcumin group, **59% of patients had a reduction in PSA levels** and **14% achieved complete PSA normalisation** * **40% of patients reported symptom relief** * Adverse events were actually **higher in the placebo group** (16 of 46 patients) than the curcumin group (7 of 45 patients, p = 0.0349) * No curcumin-attributable toxicity was identified — adverse effects were attributed to docetaxel, not curcumin This is a genuinely important finding. PSA progression rate during ADT off-treatment periods is a direct clinical outcome measure, not just a surrogate. Suppressing it from 30.2% to 10.3% in a randomised controlled trial represents a three-fold reduction in progression risk during the treatment-off phase. *** **RCT 2 — PSA and Nutritional Combination: Thomas et al. (2014)** A double-blind, placebo-controlled randomised trial of a nutritional supplement containing curcumin alongside pomegranate, green tea, and broccoli (the Pomi-T trial) in men with prostate cancer on active surveillance. * Demonstrated a **significant effect on the rate of PSA progression** compared to placebo * Confirmed safety and tolerability in a watchful waiting population * One of the most widely cited positive human trials in integrative prostate cancer research The combination design means curcumin's contribution cannot be isolated, but the trial remains highly relevant — it reflects the real-world integrative context in which curcumin is most likely to be used (alongside other dietary compounds), and the result was statistically significant. *** **Phase II Trial — Docetaxel Combination in mCRPC: Negative Result (2021)** Honesty requires including this finding. A multicentre randomised Phase II study compared docetaxel alone vs docetaxel plus oral curcumin (6 g/day for 7 days per cycle) in metastatic castration-resistant prostate cancer (mCRPC). Results: * Progression-free survival: 5.3 months (placebo) vs 3.7 months (curcumin) — no significant difference (p = 0.75) * No difference in PSA response rate, overall survival, or quality of life * Curcumin absorption was confirmed — this was not a bioavailability failure The authors noted the small sample size as a potential limitation. The key learning: **standard oral curcumin at 6 g/day in the specific context of mCRPC combined with docetaxel did not show benefit in this trial**. This may reflect the limitations of standard oral formulation bioavailability at that specific intermittent dosing schedule, the advanced and aggressive nature of mCRPC, or the genuine absence of effect in this combination at this dose. It warrants honest acknowledgement — curcumin is not a universal prostate cancer treatment and should not be positioned as one. *** **NCI-Registered Phase II Trial: Post-Radical Prostatectomy** NCI trial NCI-2014-01511 registered a randomised Phase II study of curcumin versus placebo in prostate cancer patients after surgical removal of the prostate — specifically monitoring for PSA recurrence (biochemical recurrence), which is a major clinical concern in the post-surgical population. This trial confirms curcumin's entry into the formal oncology research pipeline in prostate cancer. *** ### Mechanistic Evidence in Prostate Cancer **Androgen Receptor (AR) Signalling** Curcumin directly targets androgen receptor signalling — the central driver of prostate cancer growth in both hormone-sensitive and early castration-resistant disease. Confirmed mechanisms across published studies include: * Suppression of AR gene and protein expression in LNCaP cells (hormone-sensitive prostate cancer) in a dose-dependent manner * Inhibition of R1881-androgen-induced NKX3.1 protein expression — NKX3.1 is an androgen-regulated homeobox gene overexpressed in prostate cancer * A curcumin derivative (H10) selectively inhibits 17β-HSD3 enzyme activity, lowering intratumoral testosterone production and suppressing AR-driven tumour progression * Combined curcumin + dutasteride (a 5-alpha reductase inhibitor used in prostate cancer management) synergistically reduces PSA secretion and AR expression in LNCaP cells, induces DNA damage, and enhances apoptosis — a finding with direct practical relevance for men on dutasteride **PI3K/Akt/mTOR in PTEN-Deficient Prostate Cancer** PTEN loss is one of the most common genomic events in prostate cancer (occurring in approximately 40% of cases) and directly activates the PI3K/Akt/mTOR pathway, driving treatment resistance and aggressive behaviour. Curcumin's suppression of PI3K/Akt/mTOR is therefore particularly relevant in this subgroup. **A key finding:** nanoparticle-formulated curcumin (Theracurmin®) effectively suppressed PI3K/Akt activation in a Pten-deficient mouse model, reducing proliferation in early-stage prostate lesions. Notably, this occurred **without inducing apoptosis**, suggesting a **chemopreventive rather than cytotoxic mode of action** in early-stage PTEN-deficient disease — curcumin slows lesion progression rather than killing established tumour cells. This is a clinically important distinction for men on active surveillance with known PTEN-loss pathology. Curcumin also inhibits the p110 and p85 subunits of PI3K directly and reduces Akt phosphorylation in prostate cancer cells in a dose-dependent manner — confirmed by Western blotting in independent studies. **Docetaxel Combination: Preclinical Rationale** Despite the negative Phase II mCRPC trial above, the preclinical rationale for curcumin + docetaxel is mechanistically strong and remains relevant for earlier-stage disease and different formulations: * Combined curcumin + docetaxel in DU145 and PC3 prostate cancer cell lines significantly inhibited proliferation and induced apoptosis more effectively than either agent alone * Combination modulates expression of RTKs, PI3K, phospho-AKT, NF-κB, p53, and COX-2 simultaneously — a genuinely multi-pathway effect * Curcumin nanoparticles (PLGA-curcumin) overcame docetaxel resistance in PC3 prostate cancer cells — free curcumin partially overcame resistance, nanoparticle formulation more effectively so * A Phase II abstract (AACR 2012) in 30 patients receiving docetaxel + curcumin in castration-resistant prostate cancer with or without neuroendocrine features found curcumin and docetaxel had a global action on tumours, with Chromogranin A identified as the most responsive biomarker — suggesting a specific signal in the neuroendocrine differentiation subtype that warrants further investigation **NF-κB and COX-2 in Prostate Cancer** Curcumin-treated DU-145 prostate cancer cells showed reduced NF-κB expression paired with less proliferation and increased apoptosis. NF-κB is constitutively active in many prostate cancers and is a primary driver of castration resistance — its suppression by curcumin is therefore relevant across the disease spectrum, not only in early-stage disease. **Soy Isoflavones Combination: PSA Signal** The Ide et al. (2012) study combining curcumin with soy isoflavones showed PSA reduction signals in early-stage disease — a combination with additive anti-androgen-receptor activity, as both curcumin and genistein (the primary isoflavone) target AR expression and downstream signalling via partially overlapping but distinct mechanisms. *** ### 2025 Systematic Review: Overall Summary A 2025 systematic review (Esmaeli et al.) analysing the full published evidence base for curcumin in prostate cancer confirmed: * Curcumin modulated the PI3K/Akt/mTOR pathway in **8 published studies** * NF-κB pathway in **7 studies** * AR signalling in **6 studies** * Apoptosis-related regulators in **13 studies** * Therapeutic outcomes across studies included: apoptosis, necroptosis, cell cycle arrest, migration suppression, and angiogenesis inhibition * Nanoformulations (Theracurmin®, PLGA-curcumin) demonstrated improved bioavailability and tumour-targeted delivery * Synergistic combinations with docetaxel, quercetin, and phototherapy enhanced anti-cancer effects * A separate 2024 meta-analysis (Wang et al.) confirmed curcumin significantly inhibited PCNA and MMP2 mRNA expression and reduced tumour volume and weight in prostate cancer animal models vs controls — both p < 0.0001 *** ### Practical Interpretation Curcumin's prostate cancer evidence is broader and deeper than most people will be aware of. The PSA progression suppression result from the Choi 2019 RCT (10.3% vs 30.2%, p = 0.0259) is clinically meaningful and directly relevant to men on intermittent ADT. The PI3K/PTEN mechanistic data is particularly relevant for the large proportion of prostate cancer patients with PTEN loss. The negative mCRPC docetaxel trial should be understood in context: standard oral curcumin at 6 g/day in the most advanced and treatment-resistant prostate cancer subtype is a very different scenario from adjunctive use with a quality liposomal formulation in earlier-stage or hormone-sensitive disease. The clearest applications are: men on active surveillance wanting chemopreventive pathway support (PI3K/Akt, AR, NF-κB), men on intermittent ADT seeking PSA progression suppression during off-treatment phases, and men on androgen deprivation therapy looking for adjunctive support — all of which now have at least one positive randomised controlled trial to reference. *** **References** A randomized, double-blind, placebo-controlled trial of curcumin in prostate cancer patients on intermittent ADT — Choi et al., 2019\ A double-blind, placebo-controlled randomised trial of a polyphenol-rich whole food supplement in men with prostate cancer — Thomas et al., 2014 (Pomi-T trial)\ Multicenter randomized Phase II: docetaxel plus curcumin in mCRPC — negative result, 2021\ NCI Phase II trial of curcumin vs placebo post-radical prostatectomy — NCI-2014-01511\ Curcumin in prostate cancer: systematic review of molecular mechanisms — Esmaeli et al., 2025\ Application and potential value of curcumin in prostate cancer — meta-analysis, Wang et al., 2024\ Curcumin against prostate cancer: current evidence — Termini et al., 2020\ Combinatorial effect of curcumin with docetaxel modulates apoptotic signalling — Limtrakul et al., 2017\ Curcumin nanoparticles and cytotoxicity in docetaxel-resistant prostate cancer — Basu et al., 2020\ Combined inhibitory effects of soy isoflavones and curcumin on PSA production — Ide et al., 2012\ {% hint style="warning" %} This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use. {% endhint %} {% hint style="info" %} © 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text. {% endhint %} --- # Agent Instructions: Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/curcumin-in-oncology/curcumin-evidence-by-cancer-type/prostate-cancer.md?ask= ``` The question should be specific, self-contained, and written in natural language. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.